Mandate

Vinge advises Thermo Fisher in connection with the acquisition of Olink

Vinge has advised Thermo Fisher Scientific Inc., (”Thermo Fisher”), the world leader in serving science, with annual revenue over $40 billion, in connection with its acquisition of Olink Holding AB (publ) (“Olink”).

Thermo Fisher will commence a tender offer to acquire all of the outstanding Olink common shares and all American Depositary Shares for $26.00 per common share in cash, representing $26.00 per American Depositary Share. The transaction values Olink at approximately $3.1 billion which includes net cash of approximately $143 million.

Olink is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala and the company’s shares are since 2021 traded on Nasdaq Global Market.

Vinge’s team mainly consisted of Jonas Bergström, Erik Sjöman, Samra Tesser, Linnéa Sellström and Anna Svensson (M&A and capital markets), Cecilia Möller Norstedt (litigation), Mattias Schömer and Emelie Svanberg (tax), Sam Seddigh, (employment), Daniel Wendelsson, Victoria Fredén and Hampus Peterson (FDI) and Malin Malm Waerme (IP).

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025